vTv Therapeutics (NASDAQ:VTVT) Stock Rating Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of vTv Therapeutics (NASDAQ:VTVT) from a sell rating to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.

VTVT has been the subject of several other research reports. Weiss Ratings downgraded shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. Zacks Research upgraded vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Rodman & Renshaw assumed coverage on vTv Therapeutics in a report on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price for the company. Finally, HC Wainwright reduced their target price on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $55.83.

vTv Therapeutics Price Performance

Shares of VTVT stock opened at $30.57 on Friday. vTv Therapeutics has a 1-year low of $19.50 and a 1-year high of $44.00. The company has a market cap of $120.45 million, a price-to-earnings ratio of -28.84 and a beta of 0.21. The stock has a 50 day simple moving average of $32.14 and a 200-day simple moving average of $33.90.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Analysts anticipate that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

vTv Therapeutics Company Profile

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for metabolic and inflammatory diseases. The company’s research programs are based on its proprietary drug-discovery platform and are intended to address conditions for which additional treatment options are needed.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being studied as an adjunct to insulin for people with type 1 diabetes.